Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Epigenomics AGFRA:ECX 19 10-Year Share Buyback Ratio is -25.50 as of Dec. 2025. GuruFocus rates FRA:ECX with a GF Score™ of 19/100 and a GF Value™ of €0.09 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 135 Medical Diagnostics & Research companies, Epigenomics AG ranks worse than 88.89% on this metric.
Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.
10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Epigenomics AG's current 10-Year Share Buyback Ratio was -25.50%.
FRA:ECX's 10-Year Share Buyback Ratio is ranked worse than 88.89% of 135
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.6
vs FRA:ECX: -25.50
Epigenomics AG (FRA:ECX) 10-Year Share Buyback Ratio Explanation
A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.
Be Aware
Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.
Epigenomics AG 10-Year Share Buyback Ratio Related Terms
FRA:ECX vs TMO, DHR, NTRA: 10-Year Share Buyback Ratio Comparison
For the Diagnostics & Research subindustry, Epigenomics AG's 10-Year Share Buyback Ratio, along with its competitors' market caps and 10-Year Share Buyback Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Epigenomics AG 10-Year Share Buyback Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Epigenomics AG's 10-Year Share Buyback Ratio distribution charts can be found below:
* The bar in red indicates where Epigenomics AG's 10-Year Share Buyback Ratio falls into.
Epigenomics AG 10-Year Share Buyback Ratio Calculation
This is the annualized percentage change in shares outstanding from ten years ago to the current year. The annualized percentage change is calculated with least-square regression based on the eleven years of annual data on Shares Outstanding (EOP).
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
What does a 10-Year Share Buyback Ratio of -25.50 mean?
Epigenomics AG (FRA:ECX) has a 10-Year Share Buyback Ratio of -25.50 as of Dec. 2025. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Epigenomics AG and its competitors. According to the industry distribution chart, Epigenomics AG ranks #120 out of 135 companies in the Medical Diagnostics & Research industry, placing it in the top 88.9%.
Is Epigenomics AG's 10-Year Share Buyback Ratio too high?
Epigenomics AG's current 10-Year Share Buyback Ratio is -25.50. Based on the distribution chart, Epigenomics AG ranks #120 out of 135 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Epigenomics AG has a GF Score™ of 19/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Epigenomics AG's 10-Year Share Buyback Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Epigenomics AG ranks #120 out of 135 companies for 10-Year Share Buyback Ratio. This places Epigenomics AG in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year Share Buyback Ratio for a Medical Diagnostics & Research company?
A good 10-Year Share Buyback Ratio depends on the Medical Diagnostics & Research industry context. However, 10-Year Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year Share Buyback Ratio mean?
A high 10-Year Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 10-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past ten years. It is calculated as the annualized percentage change in shares outstanding from ten years ago to the current year. View historical data for Epigenomics AG and its competitors. Epigenomics AG's current 10-Year Share Buyback Ratio is -25.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epigenomics AG stock overvalued right now?
Based on GuruFocus' analysis, Epigenomics AG (FRA:ECX) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.09, compared to a current price of €0.90 — trading 900% above its estimated fair value. The current 10-Year Share Buyback Ratio is -25.50. Epigenomics AG's overall GF Score™ is 19/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year Share Buyback Ratio calculated?
10-Year Share Buyback Ratio is calculated from a company's financial statements. For Epigenomics AG (FRA:ECX), the current 10-Year Share Buyback Ratio is -25.50 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Epigenomics AG (FRA:ECX) Overvalued in 2026?
Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued.
The current stock price of €0.90 is trading 900% above its estimated GF Value™ of €0.09.
GuruFocus considers Epigenomics AG to be Significantly Overvalued.
Key valuation signals for FRA:ECX:
10-Year Share Buyback Ratio: -25.50
GF Value™: €0.09 vs. price of €0.90 (900% above fair value)
No single metric tells the full story. See the FRA:ECX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
19GF Score
Get the complete analysis for FRA:ECX
10-Year Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ECX has been successfully added to your 
